Home › Entities › clinical_trial › A Single-center,Open-label，Dose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old (inglês)

A Single-center,Open-label，Dose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old (inglês)

clinical trial
MedicalStudy clinical_trial Q87931195
Press Enter · cited answer in seconds

A Single-center,Open-label，Dose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old (inglês)

Summary

A Single-center,Open-label，Dose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old (inglês) is a clinical trial[1].

Key Facts

  • A Single-center,Open-label，Dose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old (inglês)'s instance of is recorded as clinical trial[2].
  • A Single-center,Open-label，Dose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old (inglês)'s start time is recorded as +2020-03-19T00:00:00Z[3].
  • A Single-center,Open-label，Dose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old (inglês)'s end time is recorded as +2020-12-30T00:00:00Z[4].
  • A Single-center,Open-label，Dose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old (inglês)'s main subject is recorded as safety[5].
  • A Single-center,Open-label，Dose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old (inglês)'s main subject is recorded as Ad5-nCoV[6].
  • A Single-center,Open-label，Dose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old (inglês)'s number of participants is recorded as {'unit': '1', 'amount': '+108'}[7].
  • A Single-center,Open-label，Dose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old (inglês)'s title is recorded as A Single-center,Open-label，Dose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old[8].
  • A Single-center,Open-label，Dose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old (inglês)'s short name is recorded as PICTHA[9].
  • A Single-center,Open-label，Dose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old (inglês)'s minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}[10].
  • A Single-center,Open-label，Dose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old (inglês)'s ClinicalTrials.gov ID is recorded as NCT04313127[11].
  • A Single-center,Open-label，Dose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old (inglês)'s maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+60'}[12].
  • A Single-center,Open-label，Dose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old (inglês)'s research intervention is recorded as Ad5-nCoV[13].
  • A Single-center,Open-label，Dose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old (inglês)'s clinical trial phase is recorded as phase I clinical trial[14].
  • A Single-center,Open-label，Dose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old (inglês)'s study type is recorded as interventional study[15].

References

Programmatic citations — every numbered marker resolves to a verifiable graph row below.

Direct Wikidata claims

  1. [2] ↑ . wikidata.org.
  2. [3] ↑ . wikidata.org.
  3. [4] ↑ . wikidata.org.
  4. [5] ↑ . wikidata.org.
  5. [6] ↑ . covid-19tracker.milkeninstitute.org. Retrieved . covid-19tracker.milkeninstitute.org. Provenance: wikidata.org.
  6. [7] ↑ . wikidata.org.
  7. [8] ↑ . wikidata.org.
  8. [9] ↑ . wikidata.org.
  9. [10] ↑ . wikidata.org.
  10. [11] ↑ . wikidata.org.
  11. [12] ↑ . wikidata.org.
  12. [13] ↑ . covid-19tracker.milkeninstitute.org. Retrieved . covid-19tracker.milkeninstitute.org. Provenance: wikidata.org.
  13. [14] ↑ . wikidata.org.
  14. [15] ↑ . wikidata.org.

Class ancestry

  1. [1] ↑ . Wikidata. wikidata.org.

📑 Cite this page

Use these citations when quoting this entity in research, articles, AI prompts, or wherever provenance matters. We aggregate Wikidata + Wikipedia + authoritative open-data sources; the stitched, scored, cross-referenced view is what 4ort.xyz contributes.

APA 4ort.xyz Knowledge Graph. (2026). A Single-center,Open-label，Dose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old (inglês). Retrieved May 3, 2026, from https://4ort.xyz/entity/a-single-center-open-label-dose-escalating-phase-i-clinical-trial-to-evaluate-recombinant-novel-coronavirus-vaccine-adenovirus-type-5-vector-in-healthy-adults-aged-18-60-years-old-ingl-s-
MLA “A Single-center,Open-label，Dose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old (inglês).” 4ort.xyz Knowledge Graph, 4ort.xyz, 3 May. 2026, https://4ort.xyz/entity/a-single-center-open-label-dose-escalating-phase-i-clinical-trial-to-evaluate-recombinant-novel-coronavirus-vaccine-adenovirus-type-5-vector-in-healthy-adults-aged-18-60-years-old-ingl-s-.
BibTeX @misc{4ortxyz_a-single-center-open-label-dose-escalating-phase-i-clinical-trial-to-evaluate-recombinant-novel-coronavirus-vaccine-adenovirus-type-5-vector-in-healthy-adults-aged-18-60-years-old-ingl-s-_2026, author = {{4ort.xyz Knowledge Graph}}, title = {{A Single-center,Open-label，Dose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old (inglês)}}, year = {2026}, url = {https://4ort.xyz/entity/a-single-center-open-label-dose-escalating-phase-i-clinical-trial-to-evaluate-recombinant-novel-coronavirus-vaccine-adenovirus-type-5-vector-in-healthy-adults-aged-18-60-years-old-ingl-s-}, note = {Accessed: 2026-05-03}}
LLM prompt According to 4ort.xyz Knowledge Graph (aggregator of Wikidata, Wikipedia, and authoritative open-data sources): A Single-center,Open-label，Dose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old (inglês) — https://4ort.xyz/entity/a-single-center-open-label-dose-escalating-phase-i-clinical-trial-to-evaluate-recombinant-novel-coronavirus-vaccine-adenovirus-type-5-vector-in-healthy-adults-aged-18-60-years-old-ingl-s- (retrieved 2026-05-03)

Canonical URL: https://4ort.xyz/entity/a-single-center-open-label-dose-escalating-phase-i-clinical-trial-to-evaluate-recombinant-novel-coronavirus-vaccine-adenovirus-type-5-vector-in-healthy-adults-aged-18-60-years-old-ingl-s- · Last refreshed: